SŞSemra Demirtaş Şenlik

Semra Demirtaş Şenlik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Semra Demirtaş Şenlik has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quantitative and comparative assessment of Tc-99 m MIBI imaging in parathyroid adenomas: associations with biochemical, morphological, and histopathological

    by Semra Demirtas Senlik, Derya Cayir, Aysenur Erdem Karaoglu, Tugba Taskin Turkmenoglu, Nur Aydinbelge Dizdar, Ozlem Ozmen

  • Fluorodeoxyglucose PET/CT-derived Metabolic Peritoneal Cancer Index for survival assessment in peritoneal carcinomatosis

    by Semra Demirtaş Şenlik, Alev Noyaner Çinar, Ceren Özge Engür Uyanik, Ayşenur Erdem Karaoğlu, Osman Sütçüoğlu, Berna Öksüzoğlu, Özlem Özmen

    Objective: To evaluate the association between the Metabolically active Peritoneal Cancer Index (M-PCI) derived from 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT) and to assess its ability to predict overall survival (OS) in patients with peritoneal carcinomatosis. Methods: This retrospective study included 107 patients with pathologically confirmed peritoneal carcinomatosis who underwent 18 F-FDG PET/CT between October 2022 and July 2025. M-PCI was calculated using a PET-adapted Peritoneal Cancer Index approach based on metabolically active peritoneal lesions across 13 anatomical regions. Patients were stratified using an M-PCI cutoff value of 20, with the appropriateness of this threshold additionally explored using receiver operating characteristic analysis. Survival analysis was performed using Kaplan–Meier analysis and univariable and multivariable Cox regression models. Results: During a median follow-up of 22 months, 78 deaths (72.9%) occurred. The median OS was 9 months. M-PCI was significantly associated with OS [hazard ratio = 1.050 per unit increase; 95% confidence interval (CI) = 1.019–1.082; P = 0.001]. Patients with M-PCI > 20 had significantly worse survival compared with those with M-PCI ≤ 20 (median OS = 3 vs. 10 months; log-rank P = 0.010), with nearly a two-fold increase in mortality risk (hazard ratio = 1.94; 95% CI = 1.14–3.32; P = 0.015). The prognostic impact of M-PCI was particularly pronounced in the gynecologic subgroup. In multivariable Cox regression analysis, M-PCI remained independently associated with OS after adjustment for tumor origin, treatment, extent of disease, ascites, and timing of peritoneal carcinomatosis (adjusted hazard ratio = 1.040; 95% CI = 1.002–1.080; P = 0.042). Conclusion: M-PCI derived from 18 F-FDG PET/CT is a significant predictor of OS in patients with peritoneal carcinomatosis. By integrating metabolic activity with spatial disease distribution, M-PCI may provide clinically relevant prognostic information and improve risk stratification in this patient population.

  • Baseline fdg pet/ct-derived tumor burden and host metabolic activity predict complete metabolic response to neoadjuvant chemotherapy in ınvasive ductal breast cancer

    by Alev Cinar, Semra Demirtas Senlik, Ayberk Inanir, Ebru Tatcı, Ozlem Ozmen

    Purpose To evaluate the prognostic significance of FDG PET/CT-derived tumor burden, host metabolic activity, inflammatory biomarkers, and body composition parameters for predicting complete metabolic response (CMR) following neoadjuvant chemotherapy (NAC) in patients with invasive ductal breast cancer. Materials and methods Ninety women with histologically confirmed invasive ductal breast cancer who underwent baseline and post-treatment FDG PET/CT examinations following NAC were retrospectively included. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), brain-to-liver ratio (Brain/LR), bone marrow-to-liver ratio (BM/LR), neutrophil-to-lymphocyte ratio (NLR), and psoas muscle-to-subcutaneous fat thickness ratio (PS/SCFT) were analyzed. Correlation analyses, multivariable regression analyses, and ROC analyses were performed. Results CMR was achieved in 77 patients (85.6%), whereas 13 patients (14.4%) demonstrated residual metabolic disease. Baseline MTV and TLG were significantly higher in non-CMR patients (p=0.024 and p = 0.004, respectively). Brain/LR was significantly lower in non-responders (p = 0.007). Ki-67 demonstrated a significant inverse correlation with MTV (ρ = − 0.309, p = 0.003). In multivariable regression analysis, baseline BM/LR (β = 0.363, p = 0.017) and baseline PS/SCFT (β = − 0.268, p = 0.017) independently predicted post-treatment SUVmax. ROC analysis demonstrated AUC values of 0.705 for MTV, 0.757 for TLG, 0.734 for Brain/LR, and 0.864 for the combined predictive model. Conclusion Baseline volumetric tumor burden is strongly associated with metabolic response following NAC. Integration of tumor burden parameters with host metabolic and body composition biomarkers may improve individualized treatment-response prediction in breast cancer.

  • Open Access

    Associations of psoas muscle index and inflammatory markers with FDG PET/CT-derived metabolic response after total neoadjuvant therapy in locally advanced rectal cancer

    by Gizem Kavak, Mehmetcan Atak, Osman Sütçüoğlu, Semra Demirtaş Şenlik, Özlem Özmen, Ömür Berna Çakmak Öksüzoğlu, Yıldız Güney

    Objective: Total neoadjuvant therapy (TNT) is increasingly used for locally advanced rectal cancer, but factors associated with metabolic tumor response remain unclear. This study aimed to explore correlations between fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT)-derived metabolic tumor response and patient-related factors, including body composition, systemic inflammatory markers, and imaging-based biomarkers, in patients receiving TNT. Materials and Methods: This retrospective single-center study included 15 patients with locally advanced rectal cancer who underwent baseline and post-treatment FDG PET/CT imaging. Metabolic tumor parameters, including maximum standardized uptake value (SUVmax), standardized uptake value normalized to lean body mass mean (SULmean), total lesion glycolysis (TLG), and metabolic tumor volume (MTV), were extracted, and percentage changes were calculated. Psoas muscle area, psoas muscle index (PMI), and subcutaneous fat were measured from the CT component, while spleen-to-liver ratio (SLR), liver-to-rectus femoris ratio (LRF), and laboratory inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, and C-reactive protein (CRP), were assessed as host-related variables. Results: Significant reductions were observed in all metabolic PET/CT parameters after treatment. Psoas muscle area and PMI showed significant negative correlations with percentage changes in all four metabolic parameters, with correlation coefficients ranging from −0.614 to −0.879, suggesting that higher psoas-derived muscle measurements may be associated with greater metabolic reduction after treatment. Albumin change was significantly correlated with TLG and MTV response. In contrast, NLR, PLR, CRP, and subcutaneous fat showed no significant associations with metabolic tumor response. The SLR correlated modestly with MTV change only. Conclusion: Baseline psoas-derived muscle measurements, particularly PMI, may be associated with metabolic tumor response after TNT in locally advanced rectal cancer. These findings should be considered preliminary and hypothesis-generating and may support further evaluation of body composition assessment during pre-treatment evaluation of this patient population.

  • Rare subcutaneous metastases of papillary thyroid carcinoma revealed by 18F-FDG PET/CT

    by Semra Demirtaş Şenlik, Barış Yılmaztekin, Ayşegül Erol, Bedriye Büşra Demirel, Gülin Uçmak

  • Concordance and Discordance Between PET/CT and CEA/CA19-9 Dynamics and Their Predictive Value for Clinical Prognosis in Colorectal Cancer

    by Semra Demirtaş Şenlik, Ayşenur Erdem Karaoğlu, Ezgi Yılmaz, Özlem Aydın İsak, Dılşa Mızrak Kaya, Özlem Özmen

    Concordance and Discordance Between PET/CT and CEA/CA19-9 Dynamics and Their Predictive Value for Clinical Prognosis in Colorectal Cancer - Acta Haematologica Oncologica Turcica

  • Open Access

    Association Of Myocardial Perfusion Scintigraphy Findings With Traditional Cardiovascular Risk Factors And Heartscore

    by Semra Demirtaş Şenlik, Alev Çınar, Aysu Dursun, Seda Gülbahar Ateş, Derya Çayır

    Cardiovascular diseases are the leading global cause of morbidity and mortality, primarily due to ischemic heart disease. This study aims to investigate the relationship between myocardial perfusion scintigraphy (MPS) findings and HeartScore values, and to evaluate its association with conventional cardiovascular risk factors. In our study, patients who were referred to the Department of Nuclear Medicine for MPS between April 1 and June 30, 2024, were included. Demographic and clinical data were collected from pre-scan anamnesis forms, including age, sex, diabetes mellitus (DM), hypercholesterolemia (HL), body mass index (BMI), coronary artery disease (CAD), smoking status, and family history. HeartScore values were calculated in a total of 144 patients, including 79 (all eligible for HeartScore calculation) with ischemia and 65 randomly selected controls without ischemia, to estimate the 10-year cardiovascular risk. A p-value of < 0.05 was considered statistically significant. Out of the 1,509 patients evaluated, MPS identified ischemia in 228 cases, infarction in 40, and normal perfusion in 1,241. A statistically significant increase in the incidence of ischemia was observed in parallel with rising HeartScore values (p = 0.008). MPS findings were significantly associated with the presence of CAD, HL and BMI (p < 0.05). However, no statistically significant association was found with DM. The significant association between MPS findings and estimated future cardiovascular risk supports the use of HeartScore as a valuable pre-screening tool. The presence of known risk factors, particularly CAD and HL, significantly increased the likelihood of ischemia on MPS, whereas BMI was inversely associated.

  • Prognostic significance of liver-to-muscle FDG uptake ratio and ınflammatory biomarkers in small cell lung cancer

    by Kadriye Başkurt, Semra Demirtaş Şenlik, Galip Can Uyar, Enes Yeşilbaş, Ömür Berna Çakmak Öksüzoğlu, Osman Sütcüoğlu

    Background Small cell lung cancer (SCLC) is an aggressive malignancy frequently complicated by systemic inflammation, cachexia, and metabolic dysfunction. While 18F-FDG PET/CT is routinely used for disease staging, its potential to reflect host metabolic status through tissue-specific uptake metrics remains underexplored. We investigated the prognostic significance of the liver-to-rectus femoris mean standardized uptake value ratio (LRF) alongside systemic inflammatory markers in patients with SCLC. Methods This retrospective study included 155 newly diagnosed SCLC patients who underwent baseline 18F-FDG PET/CT prior to systemic therapy. Quantitative PET/CT metrics—particularly LRF SUVmean—were analyzed in relation to clinical characteristics, inflammatory indices (CRP-to-albumin ratio [CAR], neutrophil-to-lymphocyte ratio [NLR]), and survival outcomes. Kaplan–Meier and multivariate Cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). Results An elevated LRF ratio (≥ 3.18) was independently associated with shorter PFS (7.52 vs. 10.22 months; p = 0.047) and OS (7.85 vs. 9.40 months; p = 0.021) in extensive-stage SCLC. Similarly, patients with CAR ≥ 0.29 had significantly worse progression-free survival (7.10 vs. 11.50 months; p = 0.001) and overall survival (7.55 vs. 13.74 months; p = 0.008) compared to those with CAR < 0.29. LRF SUVmean positively correlated with CAR and negatively with serum albumin. In contrast, NLR was not significantly associated with survival outcomes. Conclusion The LRF SUVmean ratio represents a novel, noninvasive PET/CT-derived biomarker that reflects host metabolic frailty and correlates with systemic inflammation. Integration of metabolic imaging parameters such as LRF with established laboratory markers may improve prognostic stratification in SCLC and guide supportive care strategies.


  • Open Access

    The Diagnostic Accuracy of V/P Scintigraphy in Pulmonary Embolism and Superiority of V/P SPECT to V/P Planar Scintigraphy

    by Semra Demirtaş Şenlik, Gülin Uçmak, Büşra Demirel, Hülya Efetürk, İpEk Öztürk, Aykut Kürşat Fidan, Figen Güneş

    Objective: The aim of this retrospective study is to investigate the diagnostic accuracy of planar V/P scintigraphy and V/P single-photon emission computed tomography (SPECT) in patients who referred to our clinic for V/P scintigraphy with prediagnosis of pulmonary embolism (PE), as well as to investigate the contribution of V/P SPECT technique to planar V/P technique. Material and Method: The records of 204 patients, who were preliminarily diagnosed with PE within 1 year, were retrospectively reviewed. In our investigation of the diagnostic accuracy of V/P scintigraphy in for PE, we excluded three patients who only underwent perfusion scintigraphy and 20 patients whose final diagnoses could not be confirmed. This left a total of 181 patients included in the statistical analysis. Furthermore, we evaluated the contribution of SPECT to planar imaging in 48 patients, for whom V/P Scintigraphy were reported as positive and whose final diagnoses confirmed PE. Results: The sensitivity, specificity, negative predictive value, positive predictive value, and accuracy rate of V/P SPECT were calculated as 98%, 94.7%, 99.2%, 87.3%, and 95.6%, respectively. For planar scintigraphy, they were found to be 71.4%, 95.4%, 90%, 85.3%, and 88.9%, respectively. In SPECT, 13 (27.1%) patients who were not compatible with pulmonary embolism (PE) on planar imaging were found to have findings consistent with PE. In nine patients (18.8%), additional defects not observed on planar imaging were identified. Although the goodness of fit with the final diagnosis of both methods was statistically significant, SPECT (95.6%) performed better than planar (88.9%) imaging. Conclusion: Consistent with previous studies, it was found that while both imaging methods were successful, SPECT demonstrated higher diagnostic accuracy than planar scintigraphy in diagnosing PE. Therefore, it can be hypothesized that V/P scintigraphy can be safely deemed the first-choice in the diagnosis of PE.